Targeting HIF2 in Clear Cell Renal Cell Carcinoma
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Inactivation of the von Hippel-Lindau tumor-suppressor protein (pVHL) is the signature "truncal" event in clear cell renal cell carcinoma, which is the most common form of kidney cancer. pVHL is part of a ubiquitin ligase the targets the α subunit of the hypoxia-inducible factor (HIF) transcription factor for destruction when oxygen is available. Preclinical studies strongly suggest that deregulation of HIF, and particularly HIF2, drives pVHL-defective renal carcinogenesis. Although HIF2α was classically considered undruggable, structural and chemical work by Rick Bruick and Kevin Gardner at University of Texas Southwestern laid the foundation for the development of small molecule direct HIF2α antagonists (PT2385 and the related tool compound PT2399) by Peloton Therapeutics that block the dimerization of HIF2α with its partner protein ARNT1. These compounds inhibit clear cell renal cell carcinoma growth in preclinical models, and PT2385 has now entered the clinic. Nonetheless, the availability of such compounds, together with clustered regularly interspaced short palindromic repeat (CRISPR)-based gene editing approaches, has revealed a previously unappreciated heterogeneity among clear cell renal carcinomas and patient-derived xenografts with respect to HIF2 dependence, suggesting that predictive biomarkers will be needed to optimize the use of such agents in the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251
Self-citationHIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
Keith, B., Johnson, R. S., & Simon, M. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3183 · Cited by 1,693 · cited 2×
“In further support of this conclusion, HIF2a has been shown in the renal carcinoma setting to cooperate with c-Myc and to suppress p53, whereas HIF1a has the opposite effects (Keith et al. 2012).”
BackgroundDifferential Roles of Hypoxia-Inducible Factor 1α (HIF-1α) and HIF-2α in Hypoxic Gene Regulation
Hu, C.-J., Wang, L.-Y., Chodosh, L. A., Keith, B., & Simon, M. C. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.24.9361-9374.2003 · Cited by 1,386
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes
Dalgliesh, G. L., Furge, K., Greenman, C., Chen, L., Bignell, G., Butler, A., Davies, H., Edkins, S., Hardy, C., Latimer, C., et al. (2010) · Nature · doi:10.1038/nature08672 · Cited by 1,173 · cited 1×
“Intragenic HIF1a mutations have rarely been identified in clear cell renal cancers and, when tested, have uniformly been loss of function (Morris et al. 2009; Dalgliesh et al. 2010; Shen et al. 2011).”
BackgroundRaval, R. R., Lau, K. W., Tran, M. G. B., Sowter, H. M., Mandriota, S. J., Li, J.-L., Pugh, C. W., Maxwell, P. H., Harris, A. L., & Ratcliffe, P. J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5675-5686.2005 · Cited by 940
Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL
Staller, P., Sulitkova, J., Lisztwan, J., Moch, H., Oakeley, E. J., & Krek, W. (2003) · Nature · doi:10.1038/nature01874 · Cited by 870 · cited 2×
“CXCR4 has been implicated in the maintenance of clear cell renal carcinoma cancer–initiating cells, in tumor cell invasion and metastasis, and in mobilization of myeloid-derived suppressor cells that have been linked to resistance to VEGF blockade (Staller et al. 2003; Zagzag et al. 2005; Pan et al. 2006; Struckmann e…”
BackgroundMolecular basis of the VHL hereditary cancer syndrome
Kaelin, W. G. (2002) · Nature Reviews Cancer · doi:10.1038/nrc885 · Cited by 865
Self-citationInhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., & Kaelin, W. G. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00043-0 · Cited by 761 · cited 1×
“In the laboratory, activating HIF2-responsive genes, such as by expressing a HIF2a variant that cannot be prolyl-hydroxylated, can override pVHL’s tumor-suppressor activity in nude mice xenograft assays (Kondo et al. 2002; Raval et al. 2005; Biswas et al. 2010).”
BackgroundSelf-citationTargeting renal cell carcinoma with a HIF-2 antagonist
Chen, W., Hill, H., Christie, A., Kim, M. S., Holloman, E., Pavia-Jimenez, A., Homayoun, F., Ma, Y., Patel, N., Yell, P., et al. (2016) · Nature · doi:10.1038/nature19796 · Cited by 709
Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth
Kondo, K., Kim, W. Y., Lechpammer, M., & Kaelin, W. G. (2003) · PLoS Biology · doi:10.1371/journal.pbio.0000083 · Cited by 611 · cited 1×
“Conversely, down-regulating HIF2a with short-hairpin RNA (shRNA) technology suppresses tumor formation by pVHL-defective clear cell renal carcinomas in mice (Kondo et al. 2003; Zimmer et al. 2004; Gordan et al. 2008).”
BackgroundSelf-citationHypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo
Rankin, E. B., Biju, M. P., Liu, Q., Unger, T. L., Rha, J., Johnson, R. S., Simon, M. C., Keith, B., & Haase, V. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30117 · Cited by 596 · cited 2×
“…pathological changes induced after inactivating VHL in various mouse tissues has, when tested, been prevented by concurrent inactivation of HIF2a (Rankin et al. 2007, 2008, 2009) and can, when tested, be mimicked by expressing a version of HIF2a that cannot be prolyl-hydroxylated in wild-type…”
BackgroundAdam, J., Hatipoglu, E., O'Flaherty, L., Ternette, N., Sahgal, N., Lockstone, H., Baban, D., Nye, E., Stamp, G. W., Wolhuter, K., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.006 · Cited by 585 · cited 1×
“Interestingly, genetic ablation of HIF1a worsens the renal pathology associated with papillary renal cancers driven by fumarate hydratase loss in the mouse, providing a precedent for HIF1a as a renal cancer suppressor (Adam et al. 2011).”
BackgroundHIF-α effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma
Gordan, J. D., Lal, P., Dondeti, V. R., Letrero, R., Parekh, K. N., Oquendo, C. E., Greenberg, R. A., Flaherty, K. T., Rathmell, W. K., Keith, B., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.10.016 · Cited by 493 · cited 1×
“Conversely, down-regulating HIF2a with short-hairpin RNA (shRNA) technology suppresses tumor formation by pVHL-defective clear cell renal carcinomas in mice (Kondo et al. 2003; Zimmer et al. 2004; Gordan et al. 2008).”
BackgroundHIF activation identifies early lesions in VHL kidneys
Mandriota, S. J., Turner, K. J., Davies, D. R., Murray, P. G., Morgan, N. V., Sowter, H. M., Wykoff, C. C., Maher, E. R., Harris, A. L., Ratcliffe, P. J., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00071-5 · Cited by 483
On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models
Cho, H., Du, X., Rizzi, J. P., Liberzon, E., Chakraborty, A. A., Gao, W., Carvo, I., Signoretti, S., Bruick, R. K., Josey, J. A., et al. (2016) · Nature · doi:10.1038/nature19795 · Cited by 451 · cited 1×
“Cabozantinib, which inhibits KDR and c-Met, is highly active against clear cell renal carcinoma, including in patients who have failed multiple VEGF inhibitors (Choueiri et al. 2015, 2016).”
BackgroundSelf-citationGenetic and Functional Studies Implicate HIF1 α as a 14q Kidney Cancer Suppressor Gene
Shen, C., Beroukhim, R., Schumacher, S. E., Zhou, J., Chang, M., Signoretti, S., & Kaelin, W. G. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0098 · Cited by 413
Self-citationA Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma
Wallace, E. M., Rizzi, J. P., Han, G., Wehn, P. M., Cao, Z., Du, X., Cheng, T., Czerwinski, R. M., Dixon, D. D., Goggin, B. S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0473 · Cited by 336
An oxygen-regulated switch in the protein synthesis machinery
Uniacke, J., Holterman, C. E., Lachance, G., Franovic, A., Jacob, M. D., Fabian, M. R., Payette, J., Holcik, M., Pause, A., & Lee, S. (2012) · Nature · doi:10.1038/nature11055 · Cited by 319 · cited 7×
“motes the translation of EGFR (Franovic et al. 2007; Uniacke et al. 2012), whereas pVHL has been reported to promote the endocytosis and degradation of EGFR (Zhou and Yang 2011; Uniacke et al.”
BackgroundInfluentialAllosteric inhibition of hypoxia inducible factor-2 with small molecules
Scheuermann, T. H., Li, Q., Ma, H.-W., Key, J., Zhang, L., Chen, R., Garcia, J. A., Naidoo, J., Longgood, J., Frantz, D. E., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1185 · Cited by 315 · cited 6×
“Although HIF2a was classically considered undruggable, structural and chemical work by Rick Bruick and Kevin Gardner at University of Texas Southwestern laid the foundation for the development of small molecule direct HIF2a antagonists (PT2385 and the related tool compound PT2399) by Peloton Therapeutics that block th…”
BackgroundInfluentialHepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia
Kapitsinou, P. P., Liu, Q., Unger, T. L., Rha, J., Davidoff, O., Keith, B., Epstein, J. A., Moores, S. L., Erickson-Miller, C. L., & Haase, V. H. (2010) · Blood · doi:10.1182/blood-2010-02-270322 · Cited by 307
Artificial ligand binding within the HIF2α PAS-B domain of the HIF2 transcription factor
Scheuermann, T. H., Tomchick, D. R., Machius, M., Guo, Y., Bruick, R. K., & Gardner, K. H. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808092106 · Cited by 301
Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL−/− tumors
Zimmer, M., Doucette, D., Siddiqui, N., & Iliopoulos, O. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.89.2.2 · Cited by 244
Failure to prolyl hydroxylate hypoxia‐inducible factor α phenocopies VHL inactivation in vivo
Kim, W. Y., Safran, M., Buckley, M. R., Ebert, B. L., Glickman, J., Bosenberg, M., Regan, M., & Kaelin, W. G. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601300 · Cited by 235 · cited 2×
“2007, 2008, 2009) and can, when tested, be mimicked by expressing a version of HIF2a that cannot be prolyl-hydroxylated in wild-type mice (Kim et al. 2006).”
BackgroundEpigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer
Vanharanta, S., Shu, W., Brenet, F., Hakimi, A. A., Heguy, A., Viale, A., Reuter, V. E., Hsieh, J. J.-D., Scandura, J. M., & Massagué, J. (2013) · Nature Medicine · doi:10.1038/nm.3029 · Cited by 215 · cited 1×
“…and metastasis, and in mobilization of myeloid-derived suppressor cells that have been linked to resistance to VEGF blockade (Staller et al. 2003; Zagzag et al. 2005; Pan et al. 2006; Struckmann et al. 2008; Gassenmaier et al. 2013; Panka et al. 2013; Vanharanta et al. 2013; Micucci et al. 2015).”
BackgroundBiswas, S., Troy, H., Leek, R., Chung, Y.-L., Li, J.-L., Raval, R. R., Turley, H., Gatter, K., Pezzella, F., Griffiths, J. R., et al. (2010) · Journal of Oncology · doi:10.1155/2010/757908 · Cited by 89
Hainsworth, J. D., Spigel, D. R., Sosman, J. A., Burris, H. A., Farley, C., Cucullu, H., Yost, K., Hart, L. L., Sylvester, L., Waterhouse, D. M., et al. (2007) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2007.n.030 · Cited by 80 · cited 1×
“On the other hand, PDGF receptor inhibitors have not proven to be active in clear cell renal carcinoma, either alone or added to VEGF inhibitors (Polite et al. 2006; Vuky et al. 2006; Hainsworth et al. 2007; Ryan et al. 2011).”
Background
Cited by
Targeting the HIF2–VEGF axis in renal cell carcinoma
Choueiri, T. K., & Kaelin, W. G. (2020) · Nature Medicine · doi:10.1038/s41591-020-1093-z · Cited by 477
Self-citationMechanisms of hypoxia signalling: new implications for nephrology
Schödel, J., & Ratcliffe, P. J. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0182-z · Cited by 309
The EGLN-HIF O 2 -Sensing System: Multiple Inputs and Feedbacks
Ivan, M., & Kaelin, W. G. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.06.002 · Cited by 273
“Second, the presence of FIH does not prevent pVHL-defective kidney cancers from coopting the HIF program because these tumors are driven largely by HIF2 rather than HIF1 (Cho and Kaelin, 2016).”
InfluentialSelf-citationBai, R., Li, Y., Jian, L., Yang, Y., Zhao, L., & Wei, M. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01645-2 · Cited by 279
Johansson, E., Grassi, E. S., Pantazopoulou, V., Tong, B., Lindgren, D., Berg, T. J., Pietras, E. J., Axelson, H., & Pietras, A. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.049 · Cited by 121
Metadata
- Authors
- Cho, H., & Kaelin, W. G.
- Venue
- Cold Spring Harbor Symposia on Quantitative Biology
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2016
- Volume
- 81
- Pages
- 113-121
- ISSN
- 0091-7451 (ISSN-L)
- 1943-4456
- OpenAlex
- W2560629138
- Cited by
- 56
- References
- 27
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.